Search

Ionis Pharmaceuticals Inc

Fechado

SetorSaúde

56.55 3.91

Visão Geral

Variação de preço das ações

24h

Atual

Mín

53.84

Máximo

55.23

Indicadores-chave

By Trading Economics

Rendimento

-22M

-115M

Vendas

22M

268M

EPS

-0.7

Margem de lucro

-42.787

Funcionários

1,480

EBITDA

-37M

-105M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+66.32% upside

Dividendos

By Acuity

Próximos Ganhos

28 de out. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-193M

9.1B

Abertura anterior

52.64

Fecho anterior

56.55

Sentimento de Notícias

By Acuity

100%

0%

329 / 340 Ranking em Healthcare

Ionis Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de ago. de 2026, 20:03 UTC

Macro Event

Ionis Pharmaceuticals Inc shares are higher, supported by high trading volume, though they remain below their 20-day moving average and near a one-month low.

5 de ago. de 2026, 23:56 UTC

Ionis Pharmaceuticals shares are lower in after-market hours, influenced by a disappointing ADP employment report revealing only 44,000 private sector jobs added in July.

4 de ago. de 2026, 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, having reached a session low earlier. No specific news was identified to explain the movement.

3 de ago. de 2026, 20:51 UTC

Ionis Pharmaceuticals Inc. shares are trading roughly flat in after-market hours, maintaining a cumulative return of 0.02% since Monday's close.

1 de ago. de 2026, 00:06 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, recovering from recent declines amid broader market gains, including a rise in the Nikkei 225 Index.

31 de jul. de 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, supported by a notable advance in the Biotechnology sub-sector. No specific news was identified.

30 de jul. de 2026, 23:46 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours, though no specific news explains the movement amid mixed Asian equity performance and geopolitical concerns.

29 de jul. de 2026, 23:51 UTC

Ionis Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of four consecutive sessions below its 20-day moving average.

28 de jul. de 2026, 18:03 UTC

News

Ionis Pharmaceuticals shares are lower amid an investigation by Bronstein, Gewirtz & Grossman and disappointing earnings forecasts projecting a loss of $1.07 per share.

27 de jul. de 2026, 20:07 UTC

News
Social Media

Ionis Pharmaceuticals shares are lower amid an investigation into potential claims following the company's disclosure about its failed Phase-3 trial.

25 de jul. de 2026, 00:02 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, diverging from recent gains. No specific news was identified to explain the decline.

24 de jul. de 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, following a broader market decline driven by disappointing earnings from major companies and falling crude oil prices.

23 de jul. de 2026, 20:03 UTC

Ionis Pharmaceuticals Inc shares are higher during Thursday's session, continuing a notable increase since Wednesday. Trading volume is unusually high today.

22 de jul. de 2026, 22:26 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours. Broader market conditions reflect ongoing geopolitical tensions and rising crude oil prices.

21 de jul. de 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The broader market is rebounding.

20 de jul. de 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market trading, recovering from earlier lows after three consecutive daily declines. No specific news was identified.

Comparação entre Pares

Variação de preço

Ionis Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

66.32% parte superior

Previsão para 12 meses

Média 90.13 USD  66.32%

Máximo 115 USD

Mínimo 68 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Ionis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

18 ratings

15

Comprar

3

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat